A haemorrhagic stroke is a stroke that is caused by bleeding in or around the brain. Although they are less common than strokes that are caused by a blockage, they can be much more serious.
The Stroke Association held this workshop to set the priorities for haemorrhagic stroke research in the UK.
Around 15% of strokes are haemorrhagic (due to bleeding in or around the brain). This guide explains the two different types of stroke caused by a bleed, intracerebral and subarachnoid haemorrhage, and how they are diagnosed and treated.
This research will investigate 2000 drugs that are already known to be safe for use in humans to see if they could help reduce the amount of damage to the brain an intracerebral haemorrhage (a type of stroke caused by a bleed in the brain) causes.
This research aims to improve outcomes for Intracerebral Haemorrhage (ICH) patients by developing new emergency treatments to reduce swelling in the brain after ICH, and improving the care they receive.
People with stroke due to brain haemorrhage have swelling around the haemorrhage on their brain scan. More swelling worsens recovery. No treatment improves outcome after this swelling.
The programme will use biological information about cells and molecules, and information from patients, to design a study of treatment for swelling after brain haemorrhage.
Intracerebral haemorrhage (ICH) is a type of stroke, which is caused by bleeding in the brain, ultimately leading to brain damage, disability and often death. We currently know very little about the biological changes that occur in the brain after intracerebral haemorrhage.
Techniques to predict - and in future prevent - brain haemorrhage in people treated with warfarin after stroke caused by atrial fibrillation
This study will show whether more intensive lowering of blood pressure (BP) in survivors of intracerebral haemorrhage (ICH) is feasible, safe and effective in reducing brain injury. If successful, the study will pave the way for the design a larger definitive trial.
Published online first in the journal Neurology, a new study suggests that people with AF who have an ICH due to their medication have similar outcomes whether they're on a NOAC or a vitamin K antagonist drug.